Friday , 17 August 2018

Home » RESOURCES » INVESTING » Valeant, Progenics shares rise on constipation drug approval

Valeant, Progenics shares rise on constipation drug approval

Valeant Pharmaceuticals International Inc. and Progenics Pharmaceuticals Inc. said late Tuesday the Food and Drug Administration approved their drug Relistor to treat opioid-induced constipation. Valeant shares rose 3.4% to $24.35 after hours, while Progenics shares jumped 17% to $5.80. Progenics licenses Relistor to Valeant, who plans to start marketing the drug in the U.S. in the third quarter. Earlier Tuesday, Valeant said an FDA panel recommended approval for a psoriasis treatment it licenses from AstraZeneca.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Valeant, Progenics shares rise on constipation drug approval Reviewed by on . Valeant Pharmaceuticals International Inc. and Progenics Pharmaceuticals Inc. said late Tuesday the Food and Drug Administration approved their drug Relistor to Valeant Pharmaceuticals International Inc. and Progenics Pharmaceuticals Inc. said late Tuesday the Food and Drug Administration approved their drug Relistor to Rating:
scroll to top